# Seamaty

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seamaty

- Industry: Medical Devices & Equipment
- Headquarters: Chengdu, China
- Website: www.cn.seamaty.com
- Latest round: Series D (Jan 16, 2023)
- Investors on record: 8

## About

Founded in 2012 and based in Chengdu, China, Seamaty is a medical technology company that focuses on the research and development of point-of-care test (POCT) diagnostic equipment and reagents. In 2016, the company acquired EU medical device CE certification. In December 2023, the firm closed a strategic investment. As of 2023, it has more than 450 employees. The company has subsidiaries in Thailand, Russia and Egypt.

The company's main products include medical biochemical diagnostic reagent trays, fully automatic biochemical analyzer SMT-120Pro, blood gas electrolyte analyzer SG1 and animal biochemical analyzers, etc. Animal biochemical analyzers provide services such as biochemical testing, coagulation testing, blood gas electrolyte testing, etc. The company's products are used in industries such as medical and pet care.

## Funding rounds

- Series D, Jan 16, 2023 — Chuangyu Capital
- Series C, Dec 28, 2021 — GF Xinde Investment, Puhua Capital, Huatai Zijin Investment, Jinyuan Kuntong Equity Investment Management, FC Innovation Venture Fund
- Series B, Sep 3, 2018 — Hillhouse Investment
- Series A, Jun 28, 2017 — Yuantou Capital

## Investors

- Yuantou Capital (https://capitalatlas.ai/funds/yuantou-capital) — Series A
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series C
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series C
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series C
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series C
- FC Innovation Venture Fund (https://capitalatlas.ai/funds/fc-innovation-venture-fund) — Series C
- Chuangyu Capital — Series D